STAT+: RFK Jr. backs off some MAHA issues
Stat News • 4/22/2026 – 4/23/2026
Summary
No summary yet.
Advertisement
Cluster Activity
1
1
2026-04-222026-04-23
Lindy Score Breakdown (V4.2)
6d
Age
1
Sources
from cluster
143
Hours Since Seen
Final Score2/100
CategoryAntiLindy
StatusActive
Recency Multiplier13% (0.5^143/48)
Hero EligibleYes
Story Timeline
- 2026-04-22
- 2026-04-23STAT+: RFK Jr. backs off some MAHA issues (current)
Score BreakdownRisk 50
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: 6 days - proven survivor
Stories gain Lindy status through source reputation, network consensus, and time survival.
Same Story from 2 sources
Related Stories
Breaking Similar stories
STAT+: Erasca touts strong, though preliminary, results in trial of pancreatic and lung cancer therapy
Stat News • 1 day ago
Opinion: Healthcare or health care? Help STAT decide
Stat News • Today
STAT+: Supreme Court to hear case about ‘skinny labeling’ and generic access
Stat News • 1 day ago
STAT+: Boehringer’s obesity drug shows 16.6% weight loss; more data needed
Stat News • 1 day ago
STAT+: Intellia says CRISPR-based treatment for rare disease reduced swelling attacks in pivotal trial
Stat News • 2 days ago
STAT+: Eli Lilly enlists AI startup for next-generation gene editors
Stat News • 1 day ago
STAT+: Veradermics’ hair loss drug succeeds in late-stage trial
Stat News • 2 days ago
STAT+: Dems say RFK Jr. has a pattern of failing to answer their questions
Stat News • 1 day ago
STAT+: Oruka’s long-acting psoriasis therapy posts strong results in mid-stage study
Stat News • 2 days ago
STAT+: Astellas retries XLMTM gene therapy after deaths
Stat News • 2 days ago
Anti-Lindy Similar stories
STAT+: FDA backs proposals to entice pharma companies to test, make drugs domestically
Stat News • 3 weeks ago
STAT+: Pharmalittle: We’re reading about pharma lobbying, a disappointing Novo clinical trial, and much more
Stat News • 2+ months
STAT+: Medicare chief says TrumpRx is meant to be narrow in scope
Stat News • 1+ months
STAT+: FDA panel will meet to discuss allowing broader access to certain peptides
Stat News • 2 weeks ago
STAT+: Structure Therapeutics reports significant weight loss from mid-stage GLP-1 pill
Stat News • 1+ months
STAT+: UniQure plans to seek approval for Huntington’s therapy still blocked by FDA
Stat News • 1+ months
STAT+: BioNTech founders to depart, form new mRNA-focused company
Stat News • 1+ months
STAT+: Pharmalittle: We’re reading about Lilly weight loss pill trial results, slashed U.K. clinical trial times, and more
Stat News • 1 week ago
STAT+: Pharmalittle: We’re reading about telehealth prescribers, a Lilly push against compounding, and more
Stat News • 1+ months
STAT+: Pharmalittle: We’re reading about top pharma lobbyist stepping down, genes and GLP-1 drugs, and more
Stat News • 2 weeks ago